Ef fi cient epigenetic editing of the zebra fi sh slc45a2 gene using the CRISPR/dCas9 system and tandem guide RNAs

Targeted Gene Expression Modulation Using CRISPR/dCas9 to Investigate Pathogenic Outcomes in Tomato.

Abstract A003: Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene

Examination of the predicted secondary structure of the tracrRNA–crRNA duplex suggests that the features required for Cas9-catalyzed DNA cleavage at specific sites can be captured within a single chimeric RNA.

Abstract A064: Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene

Examination of the predicted secondary structure of the tracrRNA–crRNA duplex suggests that the features required for Cas9-catalyzed DNA cleavage at specific sites can be captured within a single chimeric RNA.

Abstract A061: Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene

Examination of the predicted secondary structure of the tracrRNA–crRNA duplex suggests that the features required for Cas9-catalyzed DNA cleavage at specific sites can be captured within a single chimeric RNA.

Abstract A063: Application of CRISPR–Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with Mutations P53 gene

Examination of the predicted secondary structure of the tracrRNA–crRNA duplex suggests that the features required for Cas9-catalyzed DNA cleavage at specific sites can be captured within a single chimeric RNA.

Research Progress of CRISPR-Cas Technology in the Treatment of Monogenic Diseases

This review systematically summarizes the developmental logic, core mechanisms, clinical applications, advantages and limitations of the three generations of CRISPR-Cas technology in monogenic disorders, and analyzes the key challenges such as delivery efficiency, long-term safety, and treatment accessibility.